logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Tellus Therapeutics Secures Seed Financing To Develop The First Treatment For Newborns With White Matter Brain Injury

May 12, 2021•over 4 years ago

Round Type

seed

Durham

Description

Tellus Therapeutics, Inc., a biopharmaceutical company developing TT-20 as a treatment for white matter injury (WMI) and myelin repair in premature babies, today announced a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling work.

Company Information

Company

Tellus Therapeutics

Location

Durham, North Carolina, United States

About

As a preclinical stage life sciences start-up company, Tellus is focused on planning, funding and executing development programs to demonstrate safety and efficacy of new therapeutic interventions in critically ill newborns. Founded in October 2018, Tellus is translating breakthrough science licensed from Duke University that originated in board-certified neonatologist Eric Benner’s research laboratory in collaboration with Simon Gregory. Dr. Benner’s work identified compounds in breast milk that induce the regeneration of myelin-producing oligodendrocytes and repair WMI in animal models of perinatal brain injury. Tellus’ goal for its lead asset (TT-20) is to provide a treatment for every baby born at risk for brain injury and improve neurodevelopmental outcomes for affected children. For more information, please visit: http://www.tellustherapeutics.com.